
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is poised for success in the near future as their lead asset, pemvidutide, has the potential to address multiple diseases with a differentiated approach. The recent preliminary data from the 48-week IMPACT trial, selected as a late-breaking oral presentation at EASL, is a positive indication of the company's progress. Their strong cash position and multiple catalysts in the near-term make them an attractive investment with potential for long-term success.
Bears say
Altimmune is burdened by heavy R&D and G&A expenses that continually outpace earnings, a reliance on equity raises to support clinical development and potential commercialization, and a high risk profile, including clinical development and competition risks. While the potential of their candidate pemvidutide may diversify the company's offerings and partnerships, the uncertainty of its success, coupled with potential setbacks from COVID-19 and a challenging market landscape, make it difficult to have confidence in the company's future profitability and potential to meet key data metrics.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares